Gerresheimer, a systems and solutions provider for the pharma and biotech industries, has released its financial results for the first half of FY 2024.
Revenues reached EUR €968.5m, with revenue growth at 1.7% and adjusted EBITDA growth at 2.9% in organic terms.
The adjusted EBITDA margin was 19.4%.
The margin expansion of the Plastics & Devices division reflects a favourable product mix change, with a higher share of customised solutions.
Looking to the future
For the second half of 2024, Gerresheimer expects a significant upturn in business owing to novel production lines and the effects of destocking being less prevalent.
The company's board has confirmed its forecasts for the FYs 2024 and 2025, as well as the mid-term outlook; Gerresheimer expects to generate organic revenue growth of between 5 and 10% and an adjusted EBITDA of between €430 and 450m.
“The results of the 1st half year 2024 underpin the resilience of our business model,” says Dietmar Siemssen, CEO of Gerresheimer. “With our broad portfolio, we can offset market fluctuations in certain areas. By increasing capacity for long-term customer projects and expanding our portfolio, we will continue our profitable growth in the second half of 2024 and the years ahead.”
